Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial

Conclusions: During long-term follow-up bezafibrate-allocated patients experienced a modest but significant 10 % reduction in the adjusted risk of mortality. This effect of bezafibrate was more prominent among patients with baseline hypertriglyceridemia (25 % mortality risk reduction).

http://www.cardiab.com/content/15/1/11

Source: Cardiovascular Diabetology - January 22, 2016 Category: Cardiology Authors: Yaron ArbelRobert KlempfnerAharon ErezIlan GoldenbergSagit BenzekryNir ShlomoEnrique FismanAlexander Tenenbaumfor the BIP Study Group Source Type: research